1556 related articles for article (PubMed ID: 16856092)
1. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
Cochrane Database Syst Rev; 2006 Jul; (3):CD005326. PubMed ID: 16856092
[TBL] [Abstract][Full Text] [Related]
2. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD005326. PubMed ID: 17054253
[TBL] [Abstract][Full Text] [Related]
3. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women.
Stevenson M; Davis S; Lloyd-Jones M; Beverley C
Health Technol Assess; 2007 Feb; 11(4):1-134. PubMed ID: 17280622
[TBL] [Abstract][Full Text] [Related]
4. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.
Meunier PJ; Roux C; Ortolani S; Diaz-Curiel M; Compston J; Marquis P; Cormier C; Isaia G; Badurski J; Wark JD; Collette J; Reginster JY
Osteoporos Int; 2009 Oct; 20(10):1663-73. PubMed ID: 19153678
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men.
Kaufman JM; Audran M; Bianchi G; Braga V; Diaz-Curiel M; Francis RM; Goemaere S; Josse R; Palacios S; Ringe JD; Felsenberg D; Boonen S
J Clin Endocrinol Metab; 2013 Feb; 98(2):592-601. PubMed ID: 23341486
[TBL] [Abstract][Full Text] [Related]
6. Strontium ranelate: a novel treatment for postmenopausal osteoporosis: a review of safety and efficacy.
Blake GM; Fogelman I
Clin Interv Aging; 2006; 1(4):367-75. PubMed ID: 18046914
[TBL] [Abstract][Full Text] [Related]
7. Strontium ranelate: a new paradigm in the treatment of osteoporosis.
Reginster JY; Deroisy R; Jupsin I
Drugs Today (Barc); 2003 Feb; 39(2):89-101. PubMed ID: 12698204
[TBL] [Abstract][Full Text] [Related]
8. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
Reginster JY; Felsenberg D; Boonen S; Diez-Perez A; Rizzoli R; Brandi ML; Spector TD; Brixen K; Goemaere S; Cormier C; Balogh A; Delmas PD; Meunier PJ
Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789
[TBL] [Abstract][Full Text] [Related]
9. Treatment for osteoporosis in people with beta-thalassaemia.
Bhardwaj A; Swe KMM; Sinha NK
Cochrane Database Syst Rev; 2023 May; 5(5):CD010429. PubMed ID: 37159055
[TBL] [Abstract][Full Text] [Related]
10. Strontium ranelate in osteoporosis.
Reginster JY
Curr Pharm Des; 2002; 8(21):1907-16. PubMed ID: 12171530
[TBL] [Abstract][Full Text] [Related]
11. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.
Reginster JY; Seeman E; De Vernejoul MC; Adami S; Compston J; Phenekos C; Devogelaer JP; Curiel MD; Sawicki A; Goemaere S; Sorensen OH; Felsenberg D; Meunier PJ
J Clin Endocrinol Metab; 2005 May; 90(5):2816-22. PubMed ID: 15728210
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years.
Reginster JY; Bruyère O; Sawicki A; Roces-Varela A; Fardellone P; Roberts A; Devogelaer JP
Bone; 2009 Dec; 45(6):1059-64. PubMed ID: 19679207
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of 2 g/day of strontium ranelate in Asian women with postmenopausal osteoporosis.
Liu JM; Wai-Chee Kung A; Pheng CS; Zhu HM; Zhang ZL; Wu YY; Xu L; Meng XW; Huang ML; Chung LP; Hussain NH; Sufian SS; Chen JL
Bone; 2009 Sep; 45(3):460-5. PubMed ID: 19464401
[TBL] [Abstract][Full Text] [Related]
14. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis.
Reginster JY; Kaufman JM; Goemaere S; Devogelaer JP; Benhamou CL; Felsenberg D; Diaz-Curiel M; Brandi ML; Badurski J; Wark J; Balogh A; Bruyère O; Roux C
Osteoporos Int; 2012 Mar; 23(3):1115-22. PubMed ID: 22124575
[TBL] [Abstract][Full Text] [Related]
15. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
Meunier PJ; Roux C; Seeman E; Ortolani S; Badurski JE; Spector TD; Cannata J; Balogh A; Lemmel EM; Pors-Nielsen S; Rizzoli R; Genant HK; Reginster JY
N Engl J Med; 2004 Jan; 350(5):459-68. PubMed ID: 14749454
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D.
Hara T; Hijikata Y; Matsubara Y; Watanabe N
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013424. PubMed ID: 34231877
[TBL] [Abstract][Full Text] [Related]
17. Strontium ranelate for the management of osteoporosis.
Lam S; Zouzias K
Consult Pharm; 2008 Jul; 23(7):531-7. PubMed ID: 18764671
[TBL] [Abstract][Full Text] [Related]
18. Clinical effects of strontium ranelate in women with postmenopausal osteoporosis.
Delmas PD
Osteoporos Int; 2005 Jan; 16 Suppl 1():S16-9. PubMed ID: 15578158
[TBL] [Abstract][Full Text] [Related]
19. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
Seeman E
Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S17-20. PubMed ID: 16735841
[TBL] [Abstract][Full Text] [Related]
20. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors.
Roux C; Reginster JY; Fechtenbaum J; Kolta S; Sawicki A; Tulassay Z; Luisetto G; Padrino JM; Doyle D; Prince R; Fardellone P; Sorensen OH; Meunier PJ
J Bone Miner Res; 2006 Apr; 21(4):536-42. PubMed ID: 16598373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
